References
- Kiefel V, König C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41:766–770
- Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142:348–360
- Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484–1492
- British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10–23
- Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005;90:247–253
- Fabris F, Soini B, Sartori R, Randi ML, Luzzatto G, Girolami A. Clinical and laboratory factors that affect the post-transfusion platelet increment. Transfus Sci 2000;23:63–68
- Rebulla P, Morelati F, Revelli N, Villa MA, Paccapelo C, Nocco A, Greppi N, Marconi M, Cortelezzi A, Fracchiolla N, et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol 2004;125:83–89